1 option
Amgen : launching Repatha / Tim Calkins, Mike Harris.
- Format:
- Book
- Author/Creator:
- Calkins, Tim, author.
- Harris, Mike, author.
- Series:
- SAGE Knowledge. Cases.
- SAGE Knowledge. Cases
- Language:
- English
- Subjects (All):
- Amgen Inc.
- Heart--Diseases--Treatment--United States.
- Heart.
- Hypercholesteremia.
- Local Subjects:
- Amgen Inc.
- Physical Description:
- 1 online resource : illustrations.
- Place of Publication:
- London : Kellogg School of Management, 2017.
- Summary:
- In March 2015, Amgen is preparing for the launch of Repatha, a new molecule that has demonstrated a remarkable ability to treat high cholesterol. Through a series of clinical trials, Amgen has proven that the molecule is both safe and effective for patients with high cholesterol. It also is effective for patients with familial hypercholesterolemia, a difficult-to-treat population that has exceptionally high levels of cholesterol. Amgen expects the FDA to approve the molecule before the end of the year. Now, the Repatha team has to develop a revenue forecast.
- Notes:
- Originally published in Calkins, T., & Harris, M. (2017). Amgen: Launching Repatha. 5-416-759. Evanston, IL: Kellogg School of Management at Northwestern University.
- Description based on XML content.
- ISBN:
- 1-5264-3112-2
- 9781526431127
- OCLC:
- 1023546327
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.